Voyageur Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is December - November.

Millions CAD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 28, 2026	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021
Revenue	-	0.01	-	-	-	-
Cost of Revenue	-	0.01	-	-	-	-
Selling, General & Admin	3.34	3.53	1.7	1.34	1.75	2.05
Depreciation & Amortization Expenses	0	0	0	0	0	0
Research & Development	0.25	-	-	-	-	-
Other Operating Expenses	-	-	0.01	0.05	0.01	-
Total Operating Expenses	3.59	3.53	1.71	1.4	1.76	2.05
Operating Income	-3.59	-3.53	-1.71	-1.4	-1.76	-2.05
Other Non-Operating Income (Expense)	-	-	-	-	-0	-
Total Non-Operating Income (Expense)	-	-	-	-	-0	-
Pretax Income	-3.59	-3.53	-1.71	-1.4	-1.76	-2.05
Net Income	-3.34	-3.53	-1.71	-1.4	-1.75	-2.05
Net Income to Common	-3.34	-3.53	-1.71	-1.4	-1.75	-2.05
Shares Outstanding (Basic)	179	166	138	131	108	95
Shares Outstanding (Diluted)	179	166	138	131	108	95
Shares Change (YoY)	24.62%	20.37%	5.46%	21.03%	13.89%	34.24%
EPS (Basic)	-0.02	-0.02	-0.01	-0.01	-0.02	-0.02
EPS (Diluted)	-0.02	-0.02	-0.01	-0.01	-0.02	-0.02
Free Cash Flow	-1.68	-2.89	-0.3	-0.99	-1.72	-1.67
Free Cash Flow Per Share	-0.01	-0.02	-0.00	-0.01	-0.02	-0.02
Operating Margin	-	-30231.60%	-	-	-	-
Profit Margin	-	-30231.60%	-	-	-	-
FCF Margin	-	-24756.50%	-	-	-	-
EBITDA	-3.59	-3.53	-1.71	-1.4	-1.75	-2.04
EBITDA Margin	-	-30221.90%	-	-	-	-
EBIT	-3.59	-3.53	-1.71	-1.4	-1.76	-2.05
EBIT Margin	-	-30231.60%	-	-	-	-